Florida International University

FIU Digital Commons
HWCOM Faculty Publications

Herbert Wertheim College of Medicine

11-28-2011

Chromosomal disorders and male infertility
Gary L. Harton
Reprogenetics

Helen G. Tempest Ph.D.
Herbert Wertheim College of Medicine, Florida International University, htempest@fiu.edu

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0
License.
Follow this and additional works at: https://digitalcommons.fiu.edu/com_facpub
Part of the Medicine and Health Sciences Commons
Recommended Citation
Harton, Gary L. and Tempest, Helen G. Ph.D., "Chromosomal disorders and male infertility" (2011). HWCOM Faculty Publications.
78.
https://digitalcommons.fiu.edu/com_facpub/78

This work is brought to you for free and open access by the Herbert Wertheim College of Medicine at FIU Digital Commons. It has been accepted for
inclusion in HWCOM Faculty Publications by an authorized administrator of FIU Digital Commons. For more information, please contact
dcc@fiu.edu.

Asian Journal of Andrology (2012) 14, 32–39
ß 2012 AJA, SIMM & SJTU. All rights reserved 1008-682X/12 $32.00
www.nature.com/aja

REVIEW

Chromosomal disorders and male infertility
Gary L Harton1 and Helen G Tempest2
Infertility in humans is surprisingly common occurring in approximately 15% of the population wishing to start a family. Despite this,
the molecular and genetic factors underlying the cause of infertility remain largely undiscovered. Nevertheless, more and more genetic
factors associated with infertility are being identified. This review will focus on our current understanding of the chromosomal basis of
male infertility specifically: chromosomal aneuploidy, structural and numerical karyotype abnormalities and Y chromosomal
microdeletions. Chromosomal aneuploidy is the leading cause of pregnancy loss and developmental disabilities in humans. Aneuploidy
is predominantly maternal in origin, but concerns have been raised regarding the safety of intracytoplasmic sperm injection as infertile
men have significantly higher levels of sperm aneuploidy compared to their fertile counterparts. Males with numerical or structural
karyotype abnormalities are also at an increased risk of producing aneuploid sperm. Our current understanding of how sperm
aneuploidy translates to embryo aneuploidy will be reviewed, as well as the application of preimplantation genetic diagnosis (PGD) in
such cases. Clinical recommendations where possible will be made, as well as discussion of the use of emerging array technology in
PGD and its potential applications in male infertility.
Asian Journal of Andrology (2012) 14, 32–39; doi:10.1038/aja.2011.66; published online 28 November 2011
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INFERTILITY
Infertility is a relatively common problem that affects couples
worldwide. It is estimated that approximately 1 in 6 couples will
experience difficulties in reproducing,1,2 defined as a failure to
conceive after two years of unprotected sexual intercourse. It is
clear that fertility problems affect both males and females;3 in some
situations, the cause of the infertility is clearly defined, such as a
mechanical obstruction for example. However, for the most part, a
large proportion of infertility remains idiopathic, although more
and more genetic factors have been identified and demonstrated to
affect fertility. This review will focus on factors associated with
primary spermatogenic factors: specifically chromosomal factors
associated with male infertility will be addressed as well as the risk
of spontaneous abortions and aneuploid offspring. Chromosomal
aberrations, either numerical or structural in nature, can have
profound effects on fertility. The frequency of chromosomal
aberrations in the general population is approximately 0.6%.4
However, karyotype abnormalities are reported in 2%–14% of
males presenting with infertility.5 Increases in chromosomal aberrations have been clearly demonstrated to increase proportionally
with increasing severity of the infertility. This review will also
discuss recommendations for genetic counseling, application of
preimplantation genetic diagnosis (PGD) and perspectives on
future applications of emerging technologies and their potential
use in male infertility.

CHROMOSOMAL ANEUPLOIDY
Chromosomal aneuploidy refers to an alteration in chromosomal
number from the normal diploid chromosomal complement in somatic cells or haploid complement in gametes. Chromosomal aneuploidy is the leading cause of pregnancy loss and developmental
disabilities in humans.6 Aneuploidy can be either numerical or partial
in nature involving either gain or loss of an entire chromosomal; or
structural involving a gain or loss of a segment of a chromosome.
Numerical chromosomal aneuploidy
Chromosomal aneuploidy is, for the most part, catastrophic for
development and has been reported for all chromosomes in spontaneous abortions. In humans, aneuploidy is surprisingly common occurring in around 4% of clinically recognized pregnancies.7 However, it is
estimated that up to 60% of conceptions are aneuploid but are spontaneously aborted, often even before a pregnancy is clinically recognized.7 It is also evident that loss (monosomy) of a chromosome is
much more detrimental than gain (trisomy) of a chromosome.
Monosomy X is the only non-mosaic monosomic condition that is
compatible with life, and is largely attributed to X chromosome inactivation (Lyonization).8 In contrast, there are a handful of chromosomes (13, 18, 21, X and Y) that in a trisomic state can survive to term.
Nevertheless, it should be noted that while aneuploidy for these chromosomes is compatible with live birth, the vast majority will be spontaneously aborted early on during development.
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The genesis of chromosomal aneuploidy has been reviewed in detail
elsewhere,6,7,9,10 but in brief can occur as the result of a meiotic
non-disjunction event in gametes, precocious separation of chromatids,11–13 or as a post-zygotic mitotic non-disjunction event in the
embryo. It has long been established that advancing maternal age is
the highest risk factor for aneuploid conceptions.9 The advent of in
vitro fertilization (IVF) in conjunction with PGD has enabled the
chromosomal complement of cultured human embryos to be determined. PGD will be discussed in more detail later in subsequent sections, but in brief, the chromosomal complement of an embryo can be
determined by removing a single blastomere from 3-day-old (eightcell-stage) embryo or by removing a small bit of trophectoderm from
an embryo at the blastocyst stage. Once biopsied, the chromosomal
complement of the embryo can be determined by utilizing fluorescence in situ hybridization (FISH) on the isolated blastomere using
specific chromosome probes of interest, or, more recently, using
array-based methods to examine all 24 chromosomes. PGD has been
performed by clinics worldwide for the past two decades.14,15 The use
of PGD clinically has provided valuable information regarding the
incidence of aneuploidy in early development. This data suggest that
a high proportion of cleavage-stage embryos produced in vitro are
chromosomally abnormal, greater than 50% even in reproductively
‘young’ women, increasing to up to 80% in women over 42 years of
age.16–19 Although extended culture will eliminate some of these
abnormal embryos, a relatively high proportion continue on through
embryo development, and even at the blastocyst stage, more than half
of all embryos are abnormal (mean maternal age: 38 years).20 The
impact of aneuploidy in early embryos is illustrated by the high prevalence of chromosomal abnormalities detected in spontaneous abortions, exceeding 70% in some studies.21–26 Removal of aneuploid
embryos during assisted reproductive techniques (PGD of aneuploidy
or preimplantation genetic screening) has been proposed as a way to
improve success rates.27
To date, very little is known about the role that sperm aneuploidy
plays in infertility or assisted reproduction. Current thought is that
most aneuploidy in early embryos is predominantly derived from
female non-disjunction (,95%) or is mitotic in origin, with the
exception of aneuploidy of the sex chromosomes which is paternal
in origin in 50%–100% of cases.7 However, very little clinical
information can be found on the male contribution to aneuploidy
in cleavage-stage embryos. To date, sperm aneuploidy levels have
been assessed using FISH in over 50 studies (reviewed by Refs. 5,
28 and 29). These studies have predominantly assessed aneuploidy
levels for different chromosomes in fertile and infertile men. It is
evident from these studies that all men have a proportion of aneuploid sperm in their ejaculate. Levels of aneuploid sperm in fertile
men have been reported to be around 3%–5%; virtually all studies
investigating sperm aneuploidy levels in infertile men have demonstrated a significant increase in aneuploidy levels compared to their
fertile counterparts.5,28,29 The vast majority of studies report around
a threefold increase in sperm aneuploidy levels in infertile men.
Increases in sperm aneuploidy have been reported for all infertility
phenotypes including oligozoospermia (low concentration), asthenozoospermia (poor motility) and teratozoospermia (poor morphology). It is clear that increased frequencies are strongly correlated
with increasing severity of infertility with the highest levels reported
in men with severe oligoasthenoteratozoospermia and sperm retrieved from testicular sperm extraction in cases of non-obstructive
azoospermia.5,28,29 However, despite the increase in aneuploidy frequencies, physicians rarely order aneuploidy screening for a male

indication30 except, perhaps, for a rare case requested based on very
low sperm counts and the need for surgical or non-surgical collection of sperm from the testes. This is most likely due to the fact that
the issue of increased sperm aneuploidy in certain patient cohorts is
a complex one and raises many questions, which remain to be
answered. In particular, does increased sperm aneuploidy actually
translate to an increased risk of producing aneuploid conceptions
and how should patients with increased levels of sperm aneuploidy
be counseled?3,31–33 The following sections summarize our current
understanding of the paternal contribution of aneuploidy.
HOW DOES SPERM ANEUPLOIDY TRANSLATE TO RISK OF
ANEUPLOID OFFSPRING?
Unlike in PGD where it is possible to analyze the chromosomal
complement of a single cell derived from an embryo, at present we
have no way to assess the chromosomal complement of individual
sperm to be used in IVF or intracytoplasmic sperm injection (ICSI),
as the sperm is unfortunately destroyed in the process. Thus, even
though assessment of aneuploidy in sperm is relatively straightforward
to carry out, it is not yet clear how aneuploidy assessments can or
should be used to counsel patients.31–33 Given that we are unable to
test individual sperm to be used in IVF or ICSI, this question is
obviously difficult to address and is confounded by the large maternal
contribution to aneuploidy. Nevertheless, attempts are being made to
address this using several different approaches. To date, a handful of
studies have retrospectively assessed the levels of sperm aneuploidy in
men who have previously fathered paternally derived aneuploid offspring.34–38 These studies suggest that, in almost all cases, the levels of
aneuploidy in the sperm of these individuals are significantly higher
than those reported in normal fertile men with no history of aneuploid
offspring. One such study reported some of the highest sperm aneuploidy levels in one individual who subsequently fathered four consecutive aneuploid offspring (two of which were confirmed to be
paternal in origin).39 It is also interesting to note that there is an
apparent interchromosomal effect (ICE), as increases are frequently
reported not just for the chromosomes involved but also for other
investigated chromosomes.34 While this does not provide a direct link
between sperm aneuploidy and the likelihood of aneuploid offspring,
it has highlighted the fact that a proportion of individuals do have a
generalized tendency for non-disjunction in their sperm and that this
may result in aneuploid conceptions. Other studies have attempted to
correlate sperm aneuploidy, male infertility and reproductive outcomes. It is clear from the published data that sperm aneuploidy is
correlated with the severity of the male infertility (reviewed by Refs. 5
and 29). However, emerging data from several studies have demonstrated that higher levels of sperm aneuploidy are also associated with
recurrent ICSI failure;40,41 increased chromosomal abnormalities in
embryos;42 and lower pregnancy rates and live births.43 These studies
taken collectively do not provide direct evidence of the paternal contribution to aneuploidy, but certainly suggest that sperm aneuploidy
may play a more significant role in aneuploid conceptions than is
currently recognized in the field of reproductive medicine. In subsequent sections, we review the use of array based approaches which
have the potential to determine the paternal contribution to aneuploidy in embryos.
Mechanism and risk of producing aneuploid sperm in males
presenting with karyotype abnormalities
Individuals with karyotypic abnormalities, either numerical or structural in nature, have an obvious predisposition to chromosomally
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abnormal conceptions. As a result, they often present with infertility due to failure of achieving a successful pregnancy, often due to
repeated spontaneous abortions. The major types of karyotype
abnormalities that frequently can result in reduced fertility,
namely, chromosomal translocations or inversions, aneuploidy
and Y chromosomal microdeletions, will be discussed in further
detail.
CHROMOSOMAL TRANSLOCATIONS AND MALE INFERTILITY
Balanced chromosomal translocations involve breaks in two chromosomes and abnormal repair of the chromosomal fragments resulting in
the transposition of genetic material from one chromosome to
another without the loss of any genetic material. In the vast majority
of cases, carriers of balanced translocations are themselves phenotypically normal, unless one of the translocation breakpoints interrupts
an important gene or via position effects. Should a gene be translocated into a region in which expression is either up- or downregulated,
it can result in an increased risk of cancer, for example, the translocation could inactivate a tumor suppressor gene or activate an
oncogene.44 Nevertheless, carriers of balanced chromosomal translocations, while normal phenotypically, may experience reduced fertility, spontaneous abortions or birth defects.45 Normal meiotic
segregation of these translocations in the gametes can lead to duplication or deletion of the chromosomal regions involved in the translocation.45 Reduced fertility in translocation carriers may in part be
the result of the requirement during meiosis for chromosomal translocations to form a quadrivalent or trivalent structure (reciprocal and
Robertsonian translocations, respectively) to enable homologous
chromosomes to pair. The formation of the quadrivalent or trivalent
can lead to reduced fertility, firstly, due to the mechanics and time
constraints to form such a structure46 and secondly, as a result of the
disjunction of the structures which is prone to produce genetically
unbalanced gametes.45 The relative frequency of normal or unbalanced gametes appears to depend largely on the chromosomes
involved, the size of the region involved, the presence of heterochromatin, location of the breakpoints (e.g., G-positive or G-negative
bands) and likelihood of recombinatorial events to take place within
the translocated segments.45 The proportion of unbalanced gametes in
each balanced translocation carrier varies widely and likely reflects the
specific rearrangement involved. It should be noted that levels of
unbalanced gametes will be significantly higher than the empiric risk
of having a chromosomally unbalanced liveborn due to the fact that
many, if not most of the segregant products, will be spontaneously
aborted early on in development (depending on the chromosomes and
size of the segment involved).45
Robertsonian translocations and risk of aneuploid offspring
Robertsonian translocations involve only the acrocentric chromosomes, specifically chromosomes 13, 14, 15, 21 and 22. In this instance,
the translocation arises as the result of a centric fusion of two acrocentric chromosomes. In the case of Robertsonian translocations, we
have relatively accurate empiric risks of having liveborn affected children given that these translocations involve relatively few chromosomes, all of which have the same breakpoint.45 The frequency of
unbalanced gametes has been assessed in 20 carriers of balanced
Robertsonian translocations. The results from these studies vary
widely with reports of 3%–36% unbalanced sperm (reviewed by
Refs. 33, 47 and 48), significantly higher than the empiric risks of
having a paternally derived trisomy 13 or 21 conceptus (,2%) in each
case.
Asian Journal of Andrology

Reciprocal translocations and risk of aneuploid offspring
Reciprocal translocations involve exchanges of material between two
or more chromosomes, involving at least one non-acrocentric chromosome. In terms of genetic counseling in reciprocal translocation
carriers, the situation is much more complicated, given that the vast
majority of translocations are unique to individual families. The
sperm of 30 balanced reciprocal translocation carriers have been analyzed with much higher levels of genetically unbalanced sperm
reported, 29%–81%, compared to Robertsonian translocation carriers
(reviewed by Refs. 33, 47 and 48). The significant variation in unbalanced gametes reported likely reflects the different chromosomes
involved, size of the segments and predisposition of recombination
to occur within the translocation region.
PGD for chromosomal translocations
PGD for chromosomal translocations has been successfully applied
when FISH probes specific for the chromosomal translocation are
available. However, it should be noted that PGD by FISH is unable
to distinguish between embryos with a normal chromosomal
complement and one that is a carrier of the balanced translocation.
The European Society for Human Reproduction and Embryology
(ESHRE) PGD consortium data collection X detailed the PGD
results of 57 centers participating for the calendar year 2007 and
reported on a total of 729 cycles to oocyte retrieval for chromosomal
translocations.49 PGD for reciprocal translocations was more frequently performed than Robertsonian translocations. If we only consider oocytes that were successfully fertilized, biopsied and gave a
successful diagnostic result (n53652), only 26% (938/3652) were
transferable (normal/balanced).49 This suggests a very high level of
chromosomally unbalanced gametes (74%) and is consistent with
sperm FISH results and previous ESHRE consortium data showing
that individuals with chromosomal translocations produce a very
high rate of chromosomally abnormal embryos. In addition, several
large American PGD groups have published similar rates of unbalanced embryos and have distinguished between reciprocal and
Robertsonian translocations.50,51 These studies report 54%50 and
72%51 of embryos to be unbalanced for Robertsonian translocations,
with the percentage of unbalanced embryos for reciprocal translocations reported to be 75%50 and 82%.51 These data sets clearly provide
compelling evidence that structural chromosomal aberrations are
able to produce aneuploid gametes, and that these gametes are capable of fertilizing and in turn result in a very high proportion of
aneuploid embryos. PGD for structural rearrangements has been
very successful in assisting couples to achieve a viable unaffected
pregnancy and has certainly reduced the time taken to achieve a
pregnancy by reducing the number of spontaneous abortions.45,52
However, as FISH is not able to distinguish between normal and
balanced embryos, couples should be counseled that while any
balanced offspring will be phenotypically normal, they will likely
encounter the same fertility problems and risks of liveborn affected
children as their parents. It is clear from the published data that only
one in four embryos will be likely to be normal or balanced, and it
seems that the likelihood of a normal/balanced conception is relative
to the baseline of unbalanced gametes.
CHROMOSOMAL INVERSIONS
As with chromosomal translocations, inversions can cause infertility,
spontaneous abortions and birth defects. During meiosis, chromosomes are forced to form specialized structures (inversion loops) to
enable homologous chromosomes to pair. The formation of these
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loops can impact fertility due to the mechanics and time constraints
associated with the formation of the inversion loop.46 Single-sperm
PCR has also demonstrated that recombination within these loops is
reduced which can lead to a breakdown in meiosis53 and hence, may
lead to apoptosis of the cell leading to a reduced sperm count. In
addition, should recombination take place within the inversion loop,
this will produce a proportion of unbalanced gametes.54 As with reciprocal chromosomal translocations, the relative frequency of normal or
unbalanced gametes will depend on the chromosomes involved, the
size of the region involved and likelihood of recombinatorial events to
take place within the inverted segments. Investigations into the production of unbalanced gametes in balanced inversion carriers have
been made to a much lesser extent than translocations; nevertheless,
a handful of studies have reported ranges of unbalanced sperm of 1%–
54%.55–59
INTERCHROMOSOMAL EFFECT (ICE)
Interestingly, the presence of a structural chromosomal aberration has
in many cases exhibited an increased frequency of chromosomal
abnormalities that involve chromosomes other than those involved
in the rearrangement (reviewed by Ref. 60). This ICE refers to the
abnormal behavior of one or more chromosomes not involved in
the rearrangement. Thus, individuals with a balanced translocation
may be at an increased risk of non-disjunction events for other chromosomes as well as being at risk for aneuploidy for the segments
involved in the structural rearrangement. Studies that have investigated aneuploidy levels in the sperm of carriers of structural
chromosomal aberrations, have identified an ICE in 58% of
Robertsonian translocation carriers and 64% of reciprocal translocation carriers.60 In addition, to the increased rate of aneuploidy
observed in the sperm, PGD studies have also confirmed a higher
rate of chromosomal aneuploidy in embryos for chromosomes not
involved in the rearrangement.60
NUMERICAL SEX CHROMOSOMAL ABNORMALITIES AND
INFERTILITY
Numerical sex chromosomal abnormalities in males are relatively
common with Klinefelter syndrome (47,XXY) and 47,XYY syndrome
each occurring in approximately 1–2 in 1000 live births.61 A
high proportion of Klinefelter syndrome males are only identified
when they undergo fertility assessments. The non-mosaic form of
Klinefelter syndrome accounts for around 11% of azoospermic individuals, whereas mosaic individuals often present with oligozoospermia.62 Failure to identify Klinefelter syndrome is in part, due to the low
awareness of the condition and the misapprehension that all individuals present with the classical phenotype (tall, gynecomastia and
hypogonadism). However, it is now clear that Klinefelter syndrome
has a highly variable phenotype.44 Individuals with 47,XYY are often
fertile but appear to have an increased likelihood of infertility compared to karyotypically normal 46,XY males.63 Given the presence of
an additional sex chromosome in both Klinefelter and 47,XYY syndrome males, there is a theoretical risk of sex chromosomal aneuploidy in at least 50% of their sperm. A handful of studies have
subsequently addressed whether this is the case by analyzing the aneuploidy frequencies in the sperm of mosaic and non-mosaic Klinefelter
syndrome. For the most part, these studies all report significant
increases in sex chromosomal aneuploidy in the sperm of these individuals compared to controls, with higher frequencies reported for
non-mosaic individuals with an average of 6% aneuploidy (range:
1%–25%) versus an average of 3% (range: 0–7%) aneuploidy in

mosaic 46,XY/47,XXY individuals (reviewed by Refs. 33, 47 and 48).
In the case of 47,XYY individuals, aneuploidy levels have frequently
been reported to be significantly higher than that of karyotypically
normal men, but are often lower than those reported for Klinefelter
syndrome with an average aneuploidy level of 4% (range: 0.1%–14%)
(reviewed by Ref. 33). It is clear from these studies that some aneuploid
cells are capable of initiating and completing meiosis resulting in
aneuploid gametes. However, there does appear to be some as of yet
unknown meiotic checkpoint that is efficiently eliminating a large
proportion of aneuploid sperm. Despite this, couples should be counseled appropriately regarding the increased risk of aneuploid offspring. To date, the results are somewhat reassuring in that only
approximately 10% of published cases have resulted in aneuploid
offspring (two 47,XXY conceptuses).64,65 When PGD has been carried
out in embryos from these individuals, the level of aneuploidy
reported in sperm has been mirrored by an equivalent increase in
aneuploidies in the resulting embryos.66,67 Obviously, the number of
published studies is still relatively small for conclusions to be made and
applied for genetic counseling purposes, but as with chromosomal
translocations, there is still sufficient evidence to suggest that chromosomal abnormalities, either numerical or structural in nature, have the
ability to initiate and complete meiosis and fertilize oocytes resulting
in aneuploid conceptuses.
Y CHROMOSOMAL MICRODELETIONS AND INFERTILITY
One of the most commonly identified molecular genetic causes of
male infertility has been sub-microscopic deletions (not visible by
conventional cytogenetic analysis) on the Y chromosome. At present,
three different spermatogenetic loci azoospermia factors (AZFa, AZFb
and AZFc) have been mapped to the long arm of the Y chromosome.
Deletions within the AZF region can result in varying degrees of spermatogenic failure and hence, infertility,68 the prevalence of which
increases with the severity of infertility. Microdeletions within the
AZF region occur in approximately 4% of males with oligozoospermia; 14% of males with severe oligozoospermia; and 18% in nonobstructive azoospermia males.69 The vast majority of microdeletions
arise de novo and have been attributed to intrachromosomal homologous recombination within unstable amplicons clustered within this
region.70 Microdeletions remove one or more of these genes, and as a
result cause varying defects in spermatogenesis. Candidate genes
within the AZF regions have been studied extensively and are believed
to play critical roles in germ cell cycle regulation and meiosis.
Nevertheless, this has not yet led to the identification of the molecular
basis for defective spermatogenesis.71 Despite this, clear genotype–
phenotype correlations are emerging.72 The most common Yq microdeletions occur in the AZFc region, in part due to its relatively large
size compared to the AZFa and b, and account for approximately 60%
of reported microdeletions.44 Of these cases, about two-thirds of individuals are azoospermic, of which sperm is recoverable by testicular
sperm extraction for use in ICSI in about 50% of cases.73,74 The
remaining AZFc microdeletion cases often present with severe oligozoospermia. Deletions within the AZFa region are often the most
severe with individuals frequently presenting with Sertoli cell-only
syndrome.74,75 Various patterns of spermatogenesis arrest have been
reported with AZFb microdeletions ranging from Sertoli cell-only
syndrome to hypospermatogenesis.74,75 However, in AZFb cases, the
most frequent observation is germ cell arrest at the primary spermatocyte stage.72 When microdeletions encompass more than one region,
the genotype–phenotype correlations are unsurprisingly more complex with wide ranging spermatogenic phenotypes reported. However,
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patients with AZFb1c deletions generally have a poor success rate of
obtaining sperm for use in ICSI even through the use of testicular
sperm extraction, which has obvious clinical ramifications.76 In
addition, to the relatively large microdeletions mentioned previously, there are increasing numbers of reports of partial deletions
within the AZF regions. The most commonly reported is the gr/gr
deletion which results in the deletion of about half of the AZFc
region. The phenotypic effect of the gr/gr mutation remains somewhat controversial with some studies reporting little or no effect on
sperm concentration but an association with infertility,77 whereas
others report an association between the gr/gr mutation and oligoor azoospermia.78,79 It should be noted that mutations in genes
within the AZF region such as USP9Y have been linked to spermatogenic failure. However, reports demonstrate that these mutations
tend to be associated with a highly variable phenotype and hence, at
present, screening for these mutations should not be routinely
implemented in a clinical setting.80 Also worthy of consideration is
the unusual genomic landscape of the Y chromosome which includes
a large number of copy number variants.81,82 It has recently come to
light that these copy number variants may be associated with male
infertility.
When sperm is available for ICSI in Yq microdeletion individuals, it
is important to provide couples with appropriate genetic counseling as
the Yq microdeletion will inevitably be passed on to all of their male
offspring which will ultimately mean that all male offspring will have
reduced infertility.
SHORTCOMINGS OF PRE-ARRAY TECHNOLOGIES FOR PGD
Aneuploidy screening of embryos was first performed using FISH
analysis of cells biopsied from day-3 embryos,27,83–86 trophectoderm
cells biopsied from blastocyst stage embryos87 or polar bodies biopsied
from oocytes or zygotes.88–90 FISH-based testing was able to analyze
between 5 and 12 chromosomes in each oocyte or embryo, but was
unable to provide a full evaluation of all 24 chromosomes. It has
become clear from the conflicting studies on aneuploidy screening
using FISH-based testing that a better technology was needed to move
the field into the future and finally attain the predicted benefit of
aneuploidy screening.
Array-based testing of aneuploidy
Comparative genomic hybridization (CGH), a technique related to
FISH, was first applied to day-3 embryo biopsies in 1999.91–95 This
new technique allowed for analysis of 24 chromosomes from a single
cell and was a great leap forward from FISH-based testing. However,
conventional CGH is time-consuming and incompatible with day-3
biopsy and fresh embryo transfer in the same cycle. At the time of its
use, embryo cryopreservation was a relatively inefficient technique
and the low survival rate of frozen/thawed embryos likely eliminated
any benefits chromosomal screening may have had. For these reasons,
CGH was temporarily abandoned and FISH-based testing for aneuploidy continued for the next 8–10 years.
More recently, two new testing platforms have come into use,
microarray CGH (array-CGH (aCGH))96–99 and single nucleotide
polymorphism (SNP) microarrays.100–103 These testing platforms
allow for comprehensive chromosomal analysis of single cells from
day-3 biopsy and yield results in 24 h. The rapid turnaround time for
these methods eliminates the need to cryopreserve embryos, while
testing is carried out. The use of array-based platforms has dramatically decreased the use of FISH-based testing in most laboratories
worldwide.
Asian Journal of Andrology

aCGH is already widely used for the cytogenetic analysis of prenatal
and postnatal samples104–107 as it is rapid, cost-effective and allows
chromosomal regions to be screened at high resolution. Several types
of aCGH platform are available for the purposes of aneuploidy
screening. The variety most commonly used for the purpose of PGD
utilizes bacterial artificial chromosomal probes, about 150 000 bp in
length, covering all chromosomal bands and giving a 4 MB or lower
resolution. A microarray recently validated for PGD had 4000 probes
and thus covered ,25% of the genome sequence.103
SNPs are areas of the genome where a single nucleotide in the DNA
sequence varies within the population. Most SNPs are biallelic, existing in one of two forms, and are found scattered throughout the
genome. By determining the genotype of multiple SNPs along the
length of each chromosome, a haplotype (a contiguous series of polymorphisms on the same chromosome) can be assembled. This ultimately allows the inheritance of individual chromosomes or pieces of
chromosomes to be tracked from parents to embryos. Current SNP
microarrays simultaneously assay hundreds of thousands of SNPs,
while utilizing powerful software to distinguish how many copies of
each chromosome was inherited by an embryo.100,101,108
These new array-based testing platforms are highly informative at
multiple loci, readily automated, less subjective and theoretically less
prone to errors. All of the new generation of chromosomal screening
methods (CGH, aCGH and SNP microarrays) rely on whole genome
amplification to amplify DNA from the single cell or small number of
cells removed from a developing embryo.109
Currently, a few PGD groups around the world are validating SNP
microarrays and analysis software for clinical use in PGD for aneuploidy screening. It is expected that data from the clinical use of SNP
microarrays will closely match the data from CGH and aCGH testing.
While the technologies differ greatly, both types of arrays (CGH-based
and SNP-based) are trying to answer the same question; how many
copies of each chromosome are present in a sample?
CONCLUSIONS
The advent of ICSI in 1992110 revolutionized the treatment of male
infertility and was rapidly adopted in IVF clinics worldwide,111 as up
until this point there was little hope for infertile men to have biological
children. However, since its inception, concerns have been raised
about the safety of ICSI, especially in regard to the genetic consequences of utilizing sperm from infertile men. This is of particular
importance, given the risk of transmission of reduced fertility (Y
chromosomal microdeletions, chromosomal rearrangements) and
the risk of aneuploid offspring due to higher levels of sperm aneuploidy or unbalanced sperm in chromosomal rearrangements. Given
the aforementioned risk of chromosomal abnormalities, it would be
wise to perform routine karyotyping prior to IVF/ICSI in infertile men
with unexplained spermatogenic failure and a reduced sperm count
(less than 10 million sperm per ml); and Y chromosomal microdeletion analysis in men with severe oligozoospermia (less than 5 million
sperm per ml) or azoospermia.112,113 In a survey of the United
Kingdom IVF centers, clinicians and genetic counselors were questioned as to whether they routinely perform sperm aneuploidy screening and if they perceive there to be a genetic risk to offspring conceived
by ICSI. The vast majority indicated that while their center rarely
performed such screening, there was merit in doing so.30 However,
it is clear that we need to be able to provide more direct evidence of the
risk and identify patients who would benefit from screening to allow
patients to be appropriately counseled regarding the potential genetic
repercussions of ICSI.
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We are still a long way away from being able to answer these questions, but published studies somewhat counter-intuitively suggest that
there is little or no evidence that aneuploid sperm are at any disadvantage in fertilizing an oocyte compared to sperm with a normal haploid
complement. In fact, quite the opposite may be true as some studies
have convincingly demonstrated a distinct lack of selection against
chromosomally abnormal sperm. Albeit relatively small numbers of
studies, there is evidence to suggest that increased sperm aneuploidy
translates to increased aneuploidy in embryos. In addition, the approximate threefold increase in sperm aneuploidy we observe in infertile
populations is apparently mirrored by a threefold increase in de novo
chromosomal abnormalities in children born after ICSI.114–117 In the
case of chromosomal translocations, sperm FISH and PGD data clearly
demonstrate that a very high percentage of sperm are unbalanced and
this in turn translates to a high proportion of unbalanced embryos as
determined by PGD. Despite this, what is not yet clear is why some
individuals are predisposed to a generalized tendency for chromosomal non-disjunction or why individuals with the same phenotype,
e.g., 47,XYY syndrome, have marked variation in sperm aneuploidy
frequencies. The idea of a meiotic checkpoint has been postulated that
may function to eliminate some or the vast majority of aneuploid
gametes. If this is the case, alterations in the functioning of this checkpoint in some individuals might account for the variability in aneuploidy observed between studies. Variability in some cases is very likely
due to meiotic abnormalities, and there are certainly emerging data
suggesting that aneuploidy is closely associated with errors in chromosomal synapsis during meiosis and a reduction in meiotic recombination.118,119 In the case of individuals with numerical or structural
chromosomal aberrations, the size of the region and chromosomes
involved will undoubtedly influence chromosomal non-disjunction.
Virtually all published studies report a huge variation in sperm
aneuploidy frequencies, whether they investigate sperm aneuploidy
levels in infertile men or in individuals who are carriers of structural
chromosomal aberrations. The tremendous amount of variation
between individuals makes understandable and predictive paternal
aneuploidy risk assessments for offspring conceived by IVF/ICSI virtually impossible in a clinical situation. If we take reciprocal translocations for example, levels of unbalanced sperm reported range from
29% to 81%. Clearly, patients cannot and will not be able to make
informed decisions if given such a range. However, if individualized
sperm assessments were undertaken, an individual with 29% vs. 81%
aneuploid sperm would be given very different risk assessments. What
is apparent from the current data is that an individualized assessment
of the aneuploidy frequencies in sperm may be a more appropriate
genetic counseling tool than applying a blanket risk assessment to all
individuals with the same type of infertility or karyotype abnormality.
If performed routinely in a clinical setting, individualized assessments
of sperm aneuploidy will undoubtedly further our understanding of
paternal etiology of aneuploidy, but also be of benefit to the patient
allowing individualized estimates of risk for genetic counseling.
However, a number of drawbacks have hindered routine implementation of sperm aneuploidy clinically (reviewed by Refs. 31–33), but
briefly include: (i) the number of sperm required to be scored is
significant (minimum of 5000) and is thus costly due to its labor
intensiveness; (ii) only a handful of chromosomes (3–5) can be scored
per sperm; (iii) we are unable to test individual sperm to be used in IVF
or ICSI procedures; (iv) a direct association between sperm and
embryo aneuploidy is still not proven from the small studies to date,
thus making clinical recommendations difficult until larger, more
comprehensive studies are performed.

Despite this, what is clear is that array-based testing platforms will
potentially revolutionize our understanding of the molecular genetic
basis of infertility. SNP-based testing approaches offer a great deal
of information and insight into the genetic makeup of the sample
tested. SNP-based microarrays applied to PGD for chromosomal rearrangements can differentiate between normal and balanced (carrier)
embryos. This may allow patients that carry chromosomal rearrangements the ability to choose to transfer chromosomally normal
embryos preferentially over embryos that are balanced carriers of
the parental translocation. This preferential transfer would allow
patients to eliminate potential infertility in future generations.
However, as discussed previously, there are precious few normal/
balanced embryos diagnosed in each cycle (,25%); therefore, most
patients will not have the luxury of choosing between the two. Another
advantage of SNP-based technology is that it should also offer a single
platform for a large number of single gene defects to be tested through
PGD without the need for patient-specific test workups.100 Such
patient-specific workups can be extraordinarily time-consuming
and difficult to perform and thus delay IVF/ICSI cycles and significantly increase the cost. In addition, qualitative analysis of SNP-based
testing data may ultimately allow for analysis of parental haplotypes
and, therefore, the detection of the parental origin of any chromosomal abnormalities.120 This will be valuable in determining the true
incidence of aneuploidy in sperm and its impact on aneuploidy in
embryos.
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